| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8784931 | Advances in Radiation Oncology | 2017 | 25 Pages |
Abstract
In this large retrospective analysis, use of WBI+RNI did not affect 5-year OS rates for women with high-risk, early stage breast cancer undergoing breast-conserving surgery and adjuvant chemotherapy, regardless of nodal status, which confirms the findings of the MA.20 trial.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Amy C. MD, Yan Heather PhD, Isabelle MD, Yu PhD, Michael C. MD, Benjamin D. MD, Thomas A. MD, Gildy V. MD, Wendy A. MD, PhD, Simona F. MD, EdM,